[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352333-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352333-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mathematical-modeling-of-combinatorial-antigen-targeting-with-multiple-car-t-cell-products-for-glioblastoma-treatment-read-online","Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment - read online","","Glioblastoma is a highly aggressive brain cancer that resists conventional therapies, while CAR T-cell treatment is limited by tumor antigen heterogeneity, the tumor microenvironment, and T-cell exhaustion. To address these constraints, a hybrid mathematical model is built using PhysiCell, combining PDE tumor microenvironment dynamics with agent-based simulations of glioblastoma and CAR T-cells. The model studies combinatorial targeting of IL-13Rα2, HER2, and EGFR, using patient-informed antigen spatial heterogeneity and comparing early, sequential, and multi-location dosing strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mathematical-modeling-of-combinatorial-antigen-targeting-with-multiple-car-t-cell-products-for-glioblastoma-treatment-read-online/352333/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mathematical-modeling-of-combinatorial-antigen-targeting-with-multiple-car-t-cell-products-for-glioblastoma-treatment-read-online/352333.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the mathematical model aim to solve for glioblastoma CAR T-cell therapy?","Question",{"text":63,"@type":64},"It addresses reduced efficacy caused by tumor antigen heterogeneity, the tumor microenvironment, and T-cell exhaustion by explicitly modeling spatial antigen expression and CAR T-cell interactions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which antigens and targeting strategies are evaluated in the study?",{"text":68,"@type":64},"The model focuses on three target antigens—IL-13Rα2, HER2, and EGFR—and compares combinatorial CAR T-cell treatments informed by spatial antigen heterogeneity.",{"name":70,"@type":61,"acceptedAnswer":71},"How do the study’s dosing strategies differ in expected effectiveness?",{"text":72,"@type":64},"The model indicates early intervention is most effective for mixed antigen expression tumors, while clustered antigen patterns can achieve comparable efficacy through sequential administration instead of simultaneous dosing.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352333,1790144657,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","npj | systems biology and applications Article  \n\n| Published in partnership with the Systems Biology Institute |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41540-025-00642-7](https://doi.org/10.1038/s41540-025-00642-7) |  |  |\n| Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment\u003Cbr> Check for updates |  |  |\n| Runpeng Li1, Michael Barish2, Margarita Gutova2, Lisa A. Feldman3, Christine E. Brown4, Russell C. Rockne1,5 & Heyrim Cho1,6  |  |  |\n| Glioblastoma is a highly aggressive and difﬁcult-to-treat brain cancer that resists conventional therapies. Recent advances in chimeric antigen receptor (CAR) T-cell therapy have shown promising potential for treating glioblastoma; however, achieving optimal efﬁcacy remains challenging due to tumor antigen heterogeneity, the tumor microenvironment, and T-cell exhaustion. In this study, we developed a mathematical model of CAR T-cell therapy for glioblastoma to explore combinatorial antigen targeting with multiple CAR T-cell treatments that take into account the spatial heterogeneity of antigen expression. Our hybrid model, created using the multicellular modeling platform PhysiCell, couples partial differential equations that describe the tumor microenvironment with agent-based models for glioblastoma and CAR T-cells. The model captures cell-to-cell interactions between the glioblastoma cells and CART-cells throughouttreatment, focusing on three target antigens–IL-13Rα2, HER2, and EGFR. We analyze tumor antigen expression heterogeneity informed by expression patterns identiﬁed from human tissues and investigate patient-speciﬁc combinatorial multiple CART-cell treatment strategies. Our model demonstrates that an early intervention is the most effective approach, especially in glioblastoma tumors characterized by mixed antigen expression. However, in tissues with clustered antigen patterns, we ﬁnd that sequential administration with speciﬁc CART-cell types can achieve efﬁcacy comparable to simultaneous administration. For instance, the percent tumor reduction is 7.1% for simultaneous administration versus 6.7% for sequential administration. In addition, spatially targeted delivery of CAR T-cells to speciﬁc tumor regions with matching antigen isan effective strategy as well, resulting in up to 19.6% greater tumor reduction with multi-location administration compared to baseline injection. Our model provides a valuable platform for developing patient-speciﬁc CAR T-cell treatment plans with the potential to optimize scheduling and locations of CAR T-cell injections based on individual antigen expression proﬁles. |  |  |\n| Chimeric Antigen Receptor (CAR) T-cell therapy is regarded as one of the most effective forms of adoptive cell-based immunotherapy for cancer treatment, with FDA approval occurring in 20171–3. While CAR T-cell therapyhas proven highly effective in treatingleukemiasand lymphomas4, it is particularly well-suited for hematological cancers due to the ability of | CAR T-cells to circulate through the bloodstream and lymphatic system. However, when applied to solid tumors, CART-cells face several challenges, including: the difﬁculty of delivering CAR T-cells to the tumor mass, a hostile tumor microenvironment that can inhibit T-cell activity, and tumor antigen heterogeneity4–6. Additionally, the effectiveness of CAR T-cell |  |\n\n1Department of Mathematics, University of California Riverside, Riverside, CA, USA. 2Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA. 3Division of Neurosurgery, Department of Surgery, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA. 4Department of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA. 5Department of Computational and Quantitative Medicine, Bec","cbCaikEgAC1rKBIS","https://ap.wps.com/l/cbCaikEgAC1rKBIS","pdf",4766984,12,"English","# Background\n# Mathematical model\n## Hybrid PhysiCell framework\n# Antigen targeting scenarios\n## Early intervention vs sequential vs simultaneous\n## Spatially targeted multi-location delivery\n# Key findings\n# Implications for patient-specific therapy design","[{\"question\":\"What problem does the mathematical model aim to solve for glioblastoma CAR T-cell therapy?\",\"answer\":\"It addresses reduced efficacy caused by tumor antigen heterogeneity, the tumor microenvironment, and T-cell exhaustion by explicitly modeling spatial antigen expression and CAR T-cell interactions.\"},{\"question\":\"Which antigens and targeting strategies are evaluated in the study?\",\"answer\":\"The model focuses on three target antigens—IL-13Rα2, HER2, and EGFR—and compares combinatorial CAR T-cell treatments informed by spatial antigen heterogeneity.\"},{\"question\":\"How do the study’s dosing strategies differ in expected effectiveness?\",\"answer\":\"The model indicates early intervention is most effective for mixed antigen expression tumors, while clustered antigen patterns can achieve comparable efficacy through sequential administration instead of simultaneous dosing.\"}]","Mathematical modeling of combinatorial antigen targeting with multiple CAR T-cell products for glioblastoma treatment - read online | PDF",1790099017,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3290d793427619e34b663d1190e1a33.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ed994417f6d9627d9aca23cbf4953c3.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d6fadf6512c4132eeea147edea120fb.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6ba85319b647f32a6104d40d0f93cf5.webp",980,1301]